Mustafa Zaidi, MD
Psychiatry · Richmond, TXNPI 1275775116
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 45.0% of the total. That places this record below the midpoint for psychiatry clinicians in TX, where the typical reported total is $228.
Across 3 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$25
- Neuronetics, Inc.$16
- AbbVie$15
Across 44 payments — averaging $10,447 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$361K
- Acadia Pharmaceuticals Inc$50K
- E.r. Squibb & Sons, L.L.C.$49K
What the payments were for
- Food & beverage$56100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Neuronetics, Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
How this compares
$56 in reported general payments places this provider in the 25th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium ErDivalproex Sodium | 14 | $1,132 |
| Quetiapine Fumarate | 23 | $512 |
| Haloperidol | 11 | $484 |
| Olanzapine | 17 | $346 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $240 |
| Hydroxyzine Pamoate | 29 | $234 |
| Trazodone Hcl | 36 | $216 |
| Aripiprazole | 12 | $197 |
| Bupropion XlBupropion Hcl | 13 | $94 |
| Escitalopram Oxalate | 13 | $69 |
| Lamotrigine | 12 | $36 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Richmond
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.